Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study

Real-world outcomes, treatment patterns and T790M testing rates in non-small cell lung cancer patients treated with first-line first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors from the Slovenian cohort of the REFLECT study

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR mutation-positive (EGFRm) non-small cell lung cancer (NSCLC). However, routine clinical practice is different between countries/institutions.

Bibliographic Details
Main Authors: Turnsek Nina, Devjak Rok, Edelbaher Natalija, Osrajnik Ilonka, Unk Mojca, Vidovic Dusanka, Jeric Tina, Janzic Urska
Format: Article
Language:English
Published: Sciendo 2022-08-01
Series:Radiology and Oncology
Subjects:
real-world study
non-small cell lung cancer
epidermal growth factor receptor
t790m testing
attrition
Online Access:https://doi.org/10.2478/raon-2022-0025

Internet

https://doi.org/10.2478/raon-2022-0025

Similar Items